Predictive value of folate receptor-positive circulating tumor cells in postoperative progressive disease of non-small cell lung cancer patients.
Blood-based tumor cell markers show promise for predicting lung cancer recurrence, though prospective studies are needed before clinical use.
Folate receptor-positive CTCs offer a minimally invasive liquid biopsy marker for recurrence prediction in resected NSCLC, complementing ctDNA monitoring with a distinct CTC-based approach. Small retrospective study (n=171) warrants prospective validation before clinical adoption.
What the study was
- Study design
- Retrospective cohort study
- Population
- Stage I-IIIA NSCLC patients post-radical resection; n=171
- Sample size
- 171
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Journal of cancer research and clinical oncology
Why it surfaced
FR+CTC as recurrence biomarker post-NSCLC resection; liquid biopsy interest; small retrospective cohort warrants validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.